10.14.15
Oakland, N.J.-based Collagen Matrix Inc., which makes tissue repair and regeneration products, has named Bart J. Doedens as its new CEO effective immediately. Company founder Shu-Tung Li, Ph.D., has transitioned from CEO to chief scientific officer and will remain on the company’s board of directors.
“Bart brings a wealth of experience to Collagen Matrix with a diversified background and a proven track record of accelerating top-line growth in the medical device space,” said Shu-Tung Li, Ph.D. “He is a welcome and valuable addition to Collagen Matrix’s leadership team, and I believe his expertise will be an asset to the future success of the company.”
Before joining Collagen Matrix, Doedens served as president of Biomet 3i, a dental implant manufacturer based in Palm Beach Gardens, Fla. Prior to that, he was a vice president at Sirona Dental Systems Inc. of Long Island City, N.Y., where he was responsible for leading the CAD/CAM business unit and business development. Doedens also held executive roles at Atlas Spine Inc., Biomet Inc. and Mallinckrodt Medical Inc. (which evolved into Covidien), where he led strategic expansion initiatives as well as marketing, sales and research and development efforts.
Doedens holds an M.D. from the Free University of Amsterdam and an MBA from the University of Rochester’s executive program at the University of Rotterdam.
“Bart brings a wealth of experience to Collagen Matrix with a diversified background and a proven track record of accelerating top-line growth in the medical device space,” said Shu-Tung Li, Ph.D. “He is a welcome and valuable addition to Collagen Matrix’s leadership team, and I believe his expertise will be an asset to the future success of the company.”
Before joining Collagen Matrix, Doedens served as president of Biomet 3i, a dental implant manufacturer based in Palm Beach Gardens, Fla. Prior to that, he was a vice president at Sirona Dental Systems Inc. of Long Island City, N.Y., where he was responsible for leading the CAD/CAM business unit and business development. Doedens also held executive roles at Atlas Spine Inc., Biomet Inc. and Mallinckrodt Medical Inc. (which evolved into Covidien), where he led strategic expansion initiatives as well as marketing, sales and research and development efforts.
Doedens holds an M.D. from the Free University of Amsterdam and an MBA from the University of Rochester’s executive program at the University of Rotterdam.